The Effect of Ceftriaxone in Valproic Acid-Induced Mouse Model of Autism

Basit Öğe Kaydı
dc.contributor.authorGur, Gamze
dc.contributor.authorTopuz, Ruhan Deniz
dc.contributor.authorKizilay, Gulnur
dc.date.accessioned2024-06-12T10:52:55Z
dc.date.available2024-06-12T10:52:55Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Autism is a multifactorial neurodevelopment disease and it has not been disclosed as a hypoglutamatergic or hyperglutamathergic disease. Ceftriaxone is an antibiotic that increases glutamate transporter-1 (GLT-1) expression in the brain in chronic use. In our study we aimed to investigate the effects of different doses of ceftriaxone in postnatal period in male mice exposed to valproic acid (VPA) at 12.5th day of pregnancy.Methods: A total of 96 BALB/c male mice were divided into 12 groups (n = 8 animals per group). Ceftriaxone (50, 100, 200 mg/kg/d) or saline was given to the male offsprings born from pregnant mice administered VPA and/or saline, between days 47 and 55. Dihydrokainic acid (10 mg/kg), a GLT-1 inhibitor, was administered intraperitoneally to evaluate whether GLT-1 mediates the effect of ceftriaxone. Three chamber sociability and social interaction test and the rota rod test were performed in all groups on days 54 and 55. GLT-1 levels in the hippocampus were measured by immunohistochemistry (IHC) and western blotting (WB).Results: In our study, autism-like behaviors were observed in male offsprings that were exposed to VPA in the intrauterine period. Chronic ceftriaxone administration has no curative effect on behavioral impairment seen in autism.Conclusion: Our results show that ceftriaxone did not exert significant therapeutic effect on VPA-induced mouse model of autism.en_US
dc.description.sponsorshipTrakya University Research Council [TUBAP-2017/190]en_US
dc.description.sponsorshipAcknowledgments We thank Ahmet Ulugol, ?etin Hakan Karadag, K. Duvan-Aydemir and Onur Ersoy for their support. This work was supported by a grant from Trakya University Research Council (TUBAP-2017/190) .en_US
dc.identifier.doi10.34172/apb.2022.086
dc.identifier.endpage857en_US
dc.identifier.issn2228-5881
dc.identifier.issn2251-7308
dc.identifier.issue4en_US
dc.identifier.pmid36415629en_US
dc.identifier.scopus2-s2.0-85140272454en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage850en_US
dc.identifier.urihttps://doi.org/10.34172/apb.2022.086
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18882
dc.identifier.volume12en_US
dc.identifier.wosWOS:000869198300020en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTabriz Univ Medical Sciences & Health Servicesen_US
dc.relation.ispartofAdvanced Pharmaceutical Bulletinen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAutism Spectrum Disordersen_US
dc.subjectCeftriaxoneen_US
dc.subjectGLT-1en_US
dc.subjectValproic Aciden_US
dc.subjectBeta-Lactam Antibioticsen_US
dc.subjectGlt-1 Transporteren_US
dc.subjectManaging Epilepsyen_US
dc.subjectGlutamateen_US
dc.subjectDisorderen_US
dc.subjectParietalen_US
dc.subjectTherapyen_US
dc.subjectSystemen_US
dc.titleThe Effect of Ceftriaxone in Valproic Acid-Induced Mouse Model of Autismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu